Company: PHAT
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034183
Chunk: 353

Company: Phathom Pharmaceuticals, Inc.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 8
Chunk 353
---
 common stock under ATM facility

    1,514,219

    1

    —

    14,072

    —

    14,073

    Issuance of common stock from exercises of stock options

    16,421

    —

    —

    124

    —

    124

    Issuance of common stock in connection with underwritten public offering, net

    12,793,750

    1

    —

    141,389

    —

    141,390

    Net loss

    —

    —

    —

    —

    (201,592
    )

    (201,592
    )

    Balance at December 31, 2023

    57,970,044

    $
    5

    19

    $
    855,921

    $
    (928,685
    )
     
    $
    (72,759
    )

See accompanying notes

F-6

PHATHOM PHARMACEUTICALS, INC. 

Statements of Cash Flows 

(in thousands) 

    Years EndedDecember 31,

    2024

    2023

    Cash flows from operating activities

    Net loss
     
    $
    (334,326
    )
     
    $
    (201,592
    )

    Adjustments to reconcile net loss to net cash used in operating activities:

    Depreciation and amortization

    795

    575

    Stock-based compensation

    24,047

    45,025

    Issuance of PIK interest debt

    3,775

    3,583

    Accrued interest on revenue interest financing liability

    46,111

    24,727

    Amortization of debt discount

    2,192

    1,877

    Inventory reserve

    836

    —

    Other

    5,098

    1,869

    Changes in operating assets and liabilities:

    Prepaid expenses and other current assets

    (7,672
    )

    (8,067
    )

    Accounts receivable, net

    (37,160
    )

    (1,637
    )

    Accounts payable and accrued expenses

    34,936

    6,410

    Accrued interest

    565

    292

    Operating right